A B S T R A C T
Background. The modality by which haemodialysis (HD) is delivered [arteriovenous fistula (AVF), arteriovenous graft (AVG) or central venous catheter (CVC)] varies widely and is influenced by clinical evidence, patient factors and the prevailing service configuration. The aim of this study was to determine the outcome and impact of access strategy on patient outcome by mapping out the HD journey in a cohort of incident patients. Methods. A 2-year cohort of consecutive incident HD patients from the point of referral for first dialysis access to completion of the first 365 days of HD was prospectively reviewed. Data were sought on access type; radiological, surgical and other access-related activity; bacteraemic events; admission rates and cumulative financial cost. Results. A total of 144 patients started RRT for the first time with HD over the 2-year period. All were followed up to 1 year after starting HD, generating a total of 47 753 observed HD days.
Activity prior to starting HD for the full cohort was found to average 0.92 arteriovenous (AV) access creation procedures, 0.40 CVC insertions, 0.14 interventional radiology procedures and 0.41 ultrasound examinations per patient. The small number of patients who started on an AVG had a tendency towards higher pre-HD surgical and imaging activity than those who started on an AVF or CVC.
Activity after starting HD varied greatly with the access type used at the start of HD, with AVF patients experiencing less hospitalization, procedure and imaging activity and financial costs compared with those who start HD with a CVC. Patients who started on an AVG had a tendency towards lower surgical activity rates and financial costs than those who started on a CVC. Conclusions. Providing, maintaining and dealing with the complications of HD vascular access places a significant burden of activity that is shared across nephrology, surgery and imaging services. A well-functioning AVF is associated with the lowest burden, whereas a failed AVF or CVC access is associated with the highest burden. Patient journeys are shaped by the vascular access that they use and we suggest that the contemporary pursuit of HD access should focus on delivering personalized access solutions.
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I N T R O D U C T I O N
Regular hospital haemodialysis (HD) has proven to be especially costly and much of this is attributed to the provision, maintenance and management of complications pertaining to vascular access [1] [2] [3] . The creation and maintenance of HD vascular access is complex [4] [5] [6] [7] and involves the engagement and coordination of several disciplines, each of whom may individually focus on particular clinical outcomes, including infection rates, patencies and appearance on imaging [8] [9] [10] [11] [12] .
Although there is a good understanding of many of these individual elements that underpin vascular access provision, the collective whole remains poorly understood. It is only when one considers the cumulative impact of vascular access provision from a patient perspective that the full cost to individuals and services may be determined. There is little data on the cumulative cost and impact of vascular access provision from across all these domains.
In this study we report on a cohort of incident patients starting renal replacement therapy (RRT) with HD, encompassing the dialysis access-specific workload prior to starting RRT, through to completion of each patient's first year on regular HD. We demonstrate the temporal trends of patient migration from one access method to another, the associated surgical activity, radiological activity, bacteraemic events and hospitalization. Thereafter, financial cost was tethered to the reported activity for each patient and comparisons between different access methods were drawn.
M A T E R I A L S A N D M E T H O D S

Study population
All consecutive patients in the Glasgow Renal and Transplant Unit, Glasgow, Scotland, UK starting RRT for the first time with HD between 1 July 2013 and 30 June 2015 were studied retrospectively. This cohort was served by a vascular access team comprising two vascular access nurse specialist coordinators, a core group of seven renal surgical and two vascular surgical consultants providing a 5-day elective and 24-h emergency cover, a fully staffed interventional radiologist service providing a 5-day elective and 24-h emergency cover and two dedicated vascular access ultrasound lists per week. All patients referred for vascular access were assessed by members of the nephrology, surgical or vascular access specialist nursing team with regard to whether pre-creation ultrasound imaging was deemed necessary. A 12-week guarantee time for first arteriovenous (AV) access was in force at the time of the study. All patients were routinely offered follow-up with clinical review at 2-4 weeks after AV access creation. Assessment of the access thereafter was conducted during routine outpatient clinic review or on attendance at regular HD sessions. Any concern from staff regarding the access would trigger vascular access specialist nurse review from which surgical, radiological or imaging intervention could be sought. A system of proactive routine radiological surveillance was in place for patients who had undergone arteriovenous graft (AVG) placement, who were routinely offered digital subtraction angiography every 3 months. The default cannulation method for all AV access was 'rope ladder', with 'button-hole' cannulation only being performed in a minority of selected arteriovenous fistula (AVF) patients.
The Strathclyde Electronic Renal Patient Record (SERPR) was interrogated to extract baseline demographics of the cohort as well as determine the primary HD vascular access in use for each patient for each of the HD sessions that took place from Day 1 to Day 365 of their first year on dialysis. The access method was recorded as central venous catheter (CVC) access, AVG access or AVF access. The patient cohort was sorted in order of first access method in use and the duration of use before a change in access or RRT modality occurred, thus facilitating a visual interpretation of the temporal trends of changing access methods for the full cohort.
The specific date of starting HD was noted. All surgical and radiological activity prior to the date of starting HD that related to the provision of HD access (ultrasound vein mapping, venography, ultrasound AV access, AVF/AVG surgery, declot procedures and digital subtraction angiography) was regarded as 'prior' activity. All surgical and radiological activity from the date of starting HD up to 365 days after this date was regarded as 'post' activity. All activity was determined for each patient in the cohort through interrogation of the SERPR. Surgical operation notes and picture archiving and communication system (PACS) radiological investigation report details were reviewed manually to ensure accuracy and the exclusion of duplicated data. The date for each 'post' activity was then converted into a day number from 1 to 365 before recording.
All hospital inpatient bed stays for each patient, irrespective of the reason for admission, from the date of starting HD up to 365 days were drawn from the SERPR and the dates of admission and discharge converted into day numbers between 1 and 365 before recording. Bacteraemic events were defined as positive microbiological growth from one or more blood cultures >14 days from any previous positive blood cultures and were obtained from the SERPR alongside details regarding the type and duration of antimicrobial therapy, with dates of starting and stopping antimicrobial therapy being converted into day numbers between 1 and 365 before recording.
All data recording were censored at the point of loss to follow-up, change to a non-HD method of RRT or death prior to completion of 365 days on HD.
Cost analysis
Financial impact was assessed through cross-referencing the described activity, whether undertaken as an inpatient or while an outpatient, against the National Health Service Department of Health Reference Costs 2014-2015 [13] . Additional costs for materials not indexed within this document were added, specifically, early cannulation arteriovenous graft (£600), intravascular stent (£1650) and HeRO arteriovenous graft (£BP3000). Data on hospitalization were excluded from the cost analysis.
The cumulative costs incurred over the first year on dialysis were then expressed by the incident vascular access method at the start of HD and were reported as an average cost per patient starting on that vascular access method.
Statistical analysis of categorical variables used the chisquare test and of continuous ones employed Student's t-test with a two-tailed hypothesis and significance level set at
The first 365 days on haemodialysis P < 0.05. Ethics approval was waived due to the retrospective observational nature of the data reported.
R E S U L T S
Demographics
A total of 144 consecutive patients started RRT for the first time with HD over the 2-year period. All were followed up to 1 year after starting HD, generating a total of 47 753 observed HD days. The median age at the incident HD session was 63.9 years (range 25-86). A total of 38/144 (26.4%) had diabetes listed as the primary cause of their end-stage renal disease ( Table 1 ). The proportions of primary renal diseases and subsequent patient survival were similar to those of the incident renal population reported by the Scottish Renal Registry [13] .
At Day 1, 84/144 (58.3%) patients started HD with an AVF, 5/144 (3.5%) started with an AVG and 55/144 (38.2%) started with a CVC. Over the subsequent 365 days of observation, 17/ 144 (11.8%) died, 8/144 (5.5%) were transplanted, 2/144 (1.4%) changed to peritoneal dialysis and 1/144 (0.7%) recovered native renal function, such that 116/144 (80.6%) remained on HD at 1 year. At Day 365, 77/116 (66.4%) were using an AVF, 12/116 (10.3%) were using an AVG and 27/116 (23.3%) were using a CVC.
Temporal trends of changing access modality
Changes in access modality are presented visually in Figure 1 , where five distinct groups were evident: CVC AVF prevalence fell sharply to a nadir of 52.5% between Days 39 and 47, before steadily increasing thereafter. AVF prevalence appeared to be on an upward trajectory at Day 365. AVG prevalence appeared to increase at a steady and consistent rate throughout the 365 days of observation. CVC prevalence peaked at 42.6% between Days 39 and 40 before steadily decreasing (Figure 2 ).
Prior activity
Prior activity was found to average 0.92 AV access creation procedures, 0.4 CVC insertions, 0.14 interventional radiology procedures and 0.41 ultrasound examinations per patient who started HD. Total prior AV access and CVC insertion procedures did not differ by diabetes status [diabetes, 1.33 procedures per patient versus no diabetes, 1.34 procedures per patient, P ¼ not significant (NS)] or age (age <65 years, 1.32 procedures per patient versus age !65 years, 1.33 procedures per patient, P ¼ NS). All vascular access planning, creation and maintenance activity prior to commencing HD is demonstrated for the full cohort and subgroups of AVF, AVG and CVC at first dialysis in Table 2 . Patients who ultimately started HD with an AVG did so having experienced a greater volume of AV access surgery (average 2.4 surgeries per patient), interventional radiology attempts (average 0.6 interventions per patient) and ultrasound (average 1.2 examinations per patient) than that typically experienced by patients who started on an AVF or CVC.
Analysis by incident access method
All AV access creation, CVC insertion and imaging activity prior to starting HD and all AV access creation, CVC insertion, imaging activity, bacteraemia and hospitalization for the 365 days after starting HD are demonstrated for the full cohort and the incident access subgroups in Table 2 .
After starting HD while observed activity levels were higher in those <65 years of age and those with a primary renal disease of diabetes, these were found not to be statistically significant differences (patients <65 years of age 1.96 versus 1.29 episodes per patient, P ¼ 0.15; primary renal disease of diabetes 2.08 versus 1.54 episodes per patient, P ¼ 0.1).
AV access creation, CVC insertion procedures and imaging activity were at peak levels during the first 21 days on HD, with much of the activity relating to further access establishment (AVF, AVG or CVC insertion episodes) as opposed to ultrasound or interventional imaging episodes (0.27 new access episodes per patient versus 0.07 imaging episodes per patient, P < 0.001).
With regard to total procedural and imaging activity, patients who started HD on CVC access were exposed to a consistently greater burden of activity in the first 365 days on HD compared with those who started with AVF access (2.27 episodes per patient versus 1.19 episodes per patient, P < 0.001).
A total of 26 bacteraemic events occurred during the first 365 days on HD (Figure 1) . Half of the bacteraemia events occurred within the first 66 days on HD, and bacteraemia was most prevalent in patients who started HD on a CVC (CVC The first 365 days on haemodialysis 0.29 bacteraemic episodes per patient versus AVF 0.12 bacteraemic episodes per patient, P ¼ 0.04). In patients who started HD on a CVC, half of the bacteraemia occurred within the first 40 days on HD. A total of 323 admissions occurred over the 365 days of follow-up with a median of 2.0 admissions per patient and 9.0 inpatient days (range 0-93) per admission (Figure 1 ). In total, 2466/47 753 (5.2%) days were spent in hospital during the first year of HD. Hospitalization was greatest at starting HD, where 37/144 (25.7%) of the cohort were inpatient, and this was most pronounced in patients who started HD via CVC [CVC 26/55 (47.3%) versus AVG 1/5 (20%), P ¼ 0.34, versus AVF 10/84 (11.9%), P < 0.05].
Analysis by prevalent access method
During the 1-year period of follow-up, HD via a CVC accounted for 16 983/47 753 (35.6%), AVG 3055/44 753 (6.4%) and AVF 27 715/47 753 (58.0%) of observed days.
All AV access creation, CVC insertions, imaging activity, bacteraemia, hospitalization, transplantation and mortality for the 365 days after starting HD is expressed for the whole cohort and each prevalent access subgroup as activities per 1000 days in Table 3 .
Financial impact
The financial cost of all inpatient and outpatient AV access creation, CVC insertions, imaging activity and bacteraemic events is expressed for the full cohort and incident HD access subgroups in Table 4 .
Before initiating dialysis, the incident AVG group had more than double the expenditure per patient on access provision compared with the AVF and CVC groups (£6399.18 versus £2510.26 versus £1676.86, respectively). After starting HD however, there was difference in costs per patient between the incident AVG and AVF groups, while the incident CVC group exhibited higher costs (£4235.88 versus £2667.62 versus £5791.47, respectively).
D I S C U S S I O N
This study comprehensively details the considerable multidisciplinary activity and cost of providing, maintaining and treating complications associated with HD vascular access. These data allow visual representation of the summation and temporal trends, of the entirety of treatment that is provided and that our patients endure.
The unit studied provides access for seven HD centres and has a relatively stable population size with few patients moving out of the regional catchment area. A complete data set exists on the electronic patient record. The unit aimed for AV access in all patients where possible, with an AVF as the primary desired modality, AVG for selected patients and tunnelled CVC where frailty and life expectancy were deemed to limit treatment options. All vascular access activity and outcomes are monitored and captured electronically with HD data automatically entered into a dialysis-specific section of the electronic patient record. The proportional use of AVF and CVC access is typical of a moderate-sized UK nephrology centre. As such, the data presented are accurate, complete and representative of other centres of a similar size.
It is vital that in considering the activity or outcomes associated with vascular access that the cohort being studied is representative and that all relevant activity is captured. Vascular access provision may begin a long time before the date of starting HD, which in itself is widely variable and can vary with physician preference, patient factors and estimates of renal dysfunction. In this study, one-third of patients who started HD on a CVC had undergone prior attempts at vascular access creation, and patients who started on an AVG had undergone several attempts at AVF creation prior to receiving an AVG. Thus a strength of this analysis is that it includes pre-as well as post-RRT initiation activity.
It is also vital to avoid selection bias that can be incurred by only considering outcomes in populations who have succesfully undergone vascular access creation. This analysis studied an entire incident HD cohort defined by their need for RRT with imaging and surgery as evidence of intention to treat for AV access fitness. In this cohort, it can therefore be seen that where the intention to treat with an AVF proved challenging to fulfil, it appears that the use of an early cannulation AVG offered an alternative to CVC usage, albeit in an AVG cohort that was relatively small in number and with follow-up restricted to 1 year on HD. Subgroups of those who remained on the same access modality throughout or switched from one modality to another during the period of observation are also demonstrated. More than half the cohort had at least one change in vascular access over the first year on HD. The period of greatest movement between access types during the incident year occurred within the first 6 weeks, often where early AVF failure led to a corresponding increase in CVC and AVG use. A nadir of AV access prevalence of 52.5% between Days 39 and 47 was found before this started to increase. Interestingly, the relatively small number of patients who received an AVG rarely changed modality within the first year on HD.
The incident access type had a significant impact on what patients experienced in the first year of HD, with the full cohort exhibiting a 1/5 risk of bacteraemia and 5% of the incident year being spent in hospital. Interestingly, diabetes and age did not appear to have much of an effect on access-related activity nor on hospitalization or bacteraemic events. Bacteraemia appeared to be 'front loaded', with the half of all events occurring within 66 days, a phenomenon experienced in both the CVC and AVF groups, contributing to absolute bacteraemia rates in this incident HD population that are higher than those reported in prevalent HD populations. Although these demographic features were not the primary aim of the study and the cohort size and duration of observation were underpowered to detect small (but potentially still clinically relevant) differences, they are consistent with observations that have been seen in HD populations [14, 15] .
The prevalent access in use had a significant bearing on what patients experienced, in keeping with the recognized differing risk-benefit profiles with regard to bacteraemia, structural complications and patency rates [16] [17] [18] . Our study suggests that these differing profiles manifest as very different vascular access journeys that patients may experience. As such, the access in use may be seen to lock patients into specific clinical-cost trajectories.
The merits of AVF access were seen to extend beyond the reduced risks of bacteraemia, with those patients starting regular HD with an AVF experiencing fewer hospitalizations, fewer procedures and imaging activity and less financial costs to services compared with those who start HD with a CVC. Once started on regular dialysis, the lowest-cost strategy was a successful AVF throughout the period of observation. Although few patients started on an AVG, none had this as a first option, and thus this group appeared quite distinct from the others. Despite this self-selection, the relatively small group of patients who started on an AVG still experienced lower activity rates, with the exception of interventional radiology work, largely driven by our local unit policy to provide routine digital subtraction angiography surveillance every 3 months to preemptively identify any structural issues, and generated lower financial costs than those who started on a CVC during the first year on HD. This finding is in keeping with a recent randomized controlled trial [19] .
There are limitations to this study. It is a retrospective analysis, albeit of prospectively recorded data, and while a reasonable volume of observed days on each main access type were generated, the AVG group was small in number, and although they grew as a proportion of the prevalent HD cohort over the year, the small number of patients and restriction of follow-up to 1 year limit the strength of conclusions that can be made with regard to outcomes for the AVG group. We did not report on incident RRT patients who started on either peritoneal dialysis or renal transplantation as their first modality. These alternative RRT modalities indirectly compete alongside HD, where high rates of either may alter the phenotype of the associated HD population and therefore may indirectly shape the observed clinical course. The cohort size and limitation of follow-up to 1 year are factors for consideration. The study represents activity in a regional transplant centre for which extrapolation onto other populations may be limited. Further considerations not captured by this study include patient-specific technical factors influencing access choice and functionality, such as vessel calibre and central venous stenosis, which may preclude AVF creation. Centre-specific capacity to deliver timely access is also a key consideration, with issues such as access to theatre space and experienced surgeons and whether CVCs are placed by physicians, nurse practitioners or radiology. Specific data on hospitalization were excluded from the cost analysis. This was because the reasons for admission were often multifactorial in which vascular access-specific complications played some, all or no part in the admission and its associated duration; and the hospitalization associated with bacteraemia, surgery and imaging work was accounted for when referencing these elements to the Department of Health Reference Cost guide, where inpatient and outpatient cost codes can be selected as appropriate.
Historically vascular access services have been driven by specialty-specific, population-level target metrics, the utility of which is unclear [20, 21] . These data demonstrate that providing, maintaining and dealing with the complications of HD vascular access places a significant burden of activity that is shared across nephrology, surgery and imaging services. Those who coordinate vascular access provision may gain clear insights into this; however, the only level at which the collective burden of this activity is consistently felt is at the level of the individual patient.
This study serves to highlight the breadth and depth of impact that this has on individual patients. We can see that the patient journey is shaped by the vascular access they use. We suggest that the contemporary pursuit of HD access should focus on providing patients with solutions where, within the context of quality of life and life expectancy, the access modality that best represents the lowest cumulative burden is pursued.
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